Fluoxetine Prevents Aβ1-42-Induced Toxicity via a Paracrine Signaling Mediated by Transforming-Growth-Factor-β1
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Selective reuptake inhibitors (SSRIs), such as fluoxetine and sertraline, increase circulating Transforming-Growth-Factor-β1 (TGF-ß1) levels in depressed patients,and are currently studied for their neuroprotective properties in Alzheimer’s disease (AD). TGF-β1 is an anti-inflammatory cytokine that exerts neuroprotective effects against ß-amyloid (Aβ)-induced neurodegeneration. In the present work the SSRI, fluoxetine, was tested for the ability to protect cortical neurons against 1µM oligomeric Aß1-42-induced toxicity. At therapeutic concentrations (100nM-1µM), fluoxetine significantly prevented Aβ-induced toxicity in mixed glia-neuronalcultures, but not in pure neuronal cultures. Though to a lesser extent, also sertraline was neuroprotective in mixed cultures, whereas serotonin (10nM-10µM) did not mimick fluoxetine effects. Glia-conditioned medium collected from astrocytes challenged with fluoxetine protected pure cortical neurons against Aβ toxicity. The effect was lost in the presence of a neutralizing antibody against TGF-ß1 in the conditioned medium, or when the specific inhibitor of type-1 TGF-β1 receptor, SB431542, was added to pure neuronal cultures. Accordingly, a 24 hr treatment of cortical astrocytes with fluoxetine promoted the release of active TGF-β1 in the culture media through the conversion of latent TGF-ß1 to mature TGF-ß1. Unlike fluoxetine, both serotonin and sertraline did not stimulate the astrocyte release of active TGF-β1. We conclude that fluoxetine is neuroprotective against Aß toxicity via a paracrine signaling mediated by TGFβ-1, which does not result from a simplistic SERT blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · cited 2×
“Neuronal cultures challenged with synthetic analogs of human oligomers of A β 1 - 42 are considered a widely accepted and reliable model of the neurodegeneration occurring in AD (Gong et al., 2003).”
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer?s disease
HYND, M. (2004) · Neurochemistry International · doi:10.1016/j.neuint.2004.03.007 · Cited by 938
β-Amyloid Monomers Are Neuroprotective
Giuffrida, M. L., Caraci, F., Pignataro, B., Cataldo, S., De Bona, P., Bruno, V., Molinaro, G., Pappalardo, G., Messina, A., Palmigiano, A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1736-09.2009 · Cited by 421
Self-citationCirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107411108 · Cited by 377 · cited 1×
“A chronic treatment with SSRIs is associated with lower cortical β -amyloid PET signal in cognitively normal elderly human subjects (Cirrito et al., 2011), and with some degree of protection against the negative effects of depression on cognition in AD patients (Rozzini et al., 2010).”
Deficiency in neuronal TGF-β signaling promotes neurodegeneration and Alzheimer’s pathology
Tesseur, I., Zou, K., Esposito, L., Bard, F., Berber, E., Can, J. V., Lin, A. H., Crews, L., Tremblay, P., Mathews, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27341 · Cited by 355
Pro- and Anti-Inflammatory Cytokine Balance in Major Depression: Effect of Sertraline Therapy
Sutcigil, L., Oktenli, C., Musabak, U., Bozkurt, A., Cansever, A., Uzun, O., Sanisoglu, S. Y., Yesilova, Z., Ozmenler, N., Ozsahin, A., et al. (2007) · Clinical and Developmental Immunology · doi:10.1155/2007/76396 · Cited by 315
The role of IL-12 and TGF-β1 in the pathophysiology of major depressive disorder
Lee, K.-M., & Kim, Y.-K. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.03.015 · Cited by 150 · cited 1×
“Among antidepressants, selective reuptake inhibitors (SSRIs), such as fluoxetine and sertraline, increase circulating TGF-β 1 levels, which are reduced in major depressed patients (Lee and Kim, 2006; Sutcigil et al., 2007).”
Fluoxetine protects neurons against microglial activation-mediated neurotoxicity
Zhang, F., Zhou, H., Wilson, B. C., Shi, J.-S., Hong, J.-S., & Gao, H.-M. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70066-9 · Cited by 123 · cited 1×
“…its neuroprotective effects, including BDNF release (Chang et al., 2006), antagonism on NMDA receptors (Vizi et al., 2013), inhibition of NF-kappa B activity (Lim et al., 2009), and inhibition of the release of pro-inflammatory factors (TNF-α , IL-1 β ) from microglial cells (Zhang et al., 2012).”
Kessing, L. V., Søndergård, L., Forman, J. L., & Andersen, P. K. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.11.020 · Cited by 113 · cited 1×
“Interestingly, a continued long-term treatment with antidepressants reduces the risk to develop AD (Kessing et al., 2009).”
Background
Cited by
Caraci, F., Spampinato, S. F., Morgese, M. G., Tascedda, F., Salluzzo, M. G., Giambirtone, M. C., Caruso, G., Munafò, A., Torrisi, S. A., Leggio, G. M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.007 · Cited by 172
Self-citationCaruso, G., Caraci, F., & Jolivet, R. B. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.004 · Cited by 110
Beta-amyloid short- and long-term synaptic entanglement
Lanni, C., Fagiani, F., Racchi, M., Preda, S., Pascale, A., Grilli, M., Allegri, N., & Govoni, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.018 · Cited by 29
Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome
Caraci, F., Iulita, M. F., Pentz, R., Flores Aguilar, L., Orciani, C., Barone, C., Romano, C., Drago, F., & Cuello, A. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.004 · Cited by 18
Self-citationHerbal medicine for psychiatric disorders: Psychopharmacology and neuroscience-based nomenclature
Tang, S. W., Tang, W. H., & Leonard, B. E. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1346279 · Cited by 11
Resolving a paradox: antidepressants, neuroinflammation, and neurodegeneration
Rajkumar, R. P. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00068 · Cited by 9
Metadata
- Authors
- Caraci, F., Tascedda, F., Merlo, S., Benatti, C., Spampinato, S. F., Munafò, A., Leggio, G. M., Nicoletti, F., Brunello, N., Drago, F., Sortino, M. A., & Copani, A.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2016-10-25
- Volume
- 7
- Pages
- 389-389
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2536297730
- Cited by
- 58
- References
- 14
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.